郭志德，副教授，博士生导师

通信地址：厦门大学分子影像暨转化医学研究中心409室

电子邮箱： gzd666888@xmu.edu.cn

研究方向：放射性分子探针与分子影像

个人简介

郭志德博士毕业于中国原子能科学研究院（导师：杜进研究员、张现忠教授）；于厦门大学公共卫生学院从事博士后研究（合作导师：张现忠教授）；2020年入职厦门大学。先后入选国家博新计划、南强拔尖人才支持计划、“雏鹰计划”拔尖人才项目。其聚焦重大疾病精准诊疗，致力于放射性诊疗创新药物的研发及临床转化。主持国家自然科学基金等多个项目。以第一作者/通讯作者在Clin Cancer Res、Angew Chem Int Ed Engl、J Med Chem、J Nucl Med、Eur J Nucl Med Mol Imaging、Redox Biology、Adv Mater等专业期刊发表研究论文80余篇；申请国内外专利30余项（含4项 PCT及2项美国专利）。作为负责人/第一发明人实现多项创新放射性探针成果的企业转化；主持了多项与著名药企合作的放射性新药研发项目，支持获得多项放射性药物国内及FDA临床试验批件。担任中国核学会同位素分会、放药分会理事等学术职务。获华夏医学科技奖、中华医学科技奖、厦门大学最富转化潜力成果奖等荣誉。主要围绕“放射性分子探针与分子影像”开展相关研究。

入选计划及主持项目

先后入选国家博新计划、南强青年拔尖人才支持计划、省高层次引进人才、“雏鹰计划”青年拔尖人才。

主持国家自然科学基金面上项目、青年项目、省科技项目、校长基金、企业合作课题等。

核素诊疗创新药物研发团队致力于通过产学研深度融合，推动放射性探针创新研发与转化，已建立起聚焦于重大疾病诊疗的独特原创放射性药物研发平台，并与国内多家医院、平台、公司合作开展放射性核素创新药物的转化研究。近年来主持多项放射性新药研发及科技成果转化项目并支持企业获得多项药品临床试验批件。多项发明人成果实现企业转化。

主要研究领域

（1）新型诊疗探针的开发研究：通过化学、生物学手段创新探针设计、优化探针性能，开发功能性、智能化分子影像探针。

（2）持续探索基于放射性药物的RadioPro-Immuno-Theranostics“联核”免疫诊疗新范式；

招生/招聘

诚挚欢迎化学、生物学、药学、医学、公共卫生、材料学等专业的优秀学子们加入核素诊疗创新药物研发团队大家庭，一起探索放射性药物及分子影像新天地！

同时，本课题组招收科研助理及放药专项研发人员，待遇从优。有意者可随时发送简历或电话联系（长期有效）。

更多信息详见课题组公众号“厦一站MIPer”

课题组近五年成果列表（^#共同一作，*通讯作者）

[51] Jingru Zhang^#, Lingxin Meng^#, Huifeng Li, Dongsheng Xia, Xiaobo Wang, Rongqiang Zhuang, Huanhuan Liu, Yesen Li*, Xianzhong Zhang*, Jianyang Fang*, Zhide Guo*. Development of ⁶⁸Ga-Labeled macrocyclic peptide for targeting stimulator of interferon genes. Acta Pharm Sin B 2026, 10.1016/j.apsb.2026.03.010

[50] Chunyu Duan^#, Shibo Guo^#, Peng Xu, Wei Han, Yu Lu, Zhide Guo*, Peng Fu*, Gang Liu*, Changjiu Zhao*. CD38-Targeted Small-Molecule PET Radiotracer for Noninvasive Tumor Burden Quantification and Dynamic Therapy Monitoring in Multiple Myeloma. Journal of Medicinal Chemistry 2026, 69: 7068–7081

[49] Lumei Huang, Shilan Peng, Huanhuan Liu, Xinying Zeng, Jianyang Fang, Yanjie Wang, Haotian Zhu, Rongqiang Zhuang, Zhide Guo*, Xianzhong Zhang*. Development of a Novel Approach for In Vivo Tumor Hypoxia PET Imaging with Nitroreductase-Specific Responsive Radiotracers. Molecular Pharmaceutics 2026, 23: 2142-2150

[48] Chenyu Peng^#, Hongwu Liu^#, Xueqi Wang, Zicheng Huang, Xianzhong Zhang*, Rongqiang Zhuang*, Zhide Guo*. H₂O₂-Responsive Organochalcogen-Based Probes for ¹⁹F Chemical Shift-Switching MRI. Analytical Chemistry 2026, 98: 5353-5361

[47] Zhexin He^#, Hongwu Liu^#, Qian Yu^#, Shihan Chen, Jiahui Sun, Yiqing Chi, Jieying, Huang, Ben Li, Mingxin Zhang, Yesen Ye, Rongqiang Zhuang, Xianzhong Zhang, Guangjie Yang*, Zhide Guo*. Quinoline/Naphthalene-Embedded PSMA Probes for Precise PET Imaging with Minimizing Undesired Retention. Journal of Medicinal Chemistry 2026, 69: 2954-2967 

[46] Tao Yang^#, Jiahui Sun^#, Guolong Huang^#, Hong Wang, Zhexin He, Siying Lin, Yanjie Wang, Rongqiang Zhuang, Xianzhong Zhang, Hongwu Liu*, Zhide Guo*. 18F/68Ga-Labeled Peptide-Based Probes for PET Imaging of ROR1 Expression. Journal of Medicinal Chemistry 2025, 68: 26049-26060

[45] Chao Wang^#, Tianrui Kang^#, Shun Hu, Zezhong Shao, Zhide Guo*, Rong Lin*, Weibing Miao*. Biodistribution and radiation dosimetry of [18F]AlF-NSFBP4 in cancer patients: first-in-human study. Clin Nucl Med. 2026, 51: 21-27.

[44] Hong Wang^#, Zhenwen Zhao^#, Xiao Xu*, Zhide Guo*, Gang Liu*. Ultra-low-dose radioimmunotherapy improves prostate cancer treatment efficacy and safety. Chinese Chemical Letters 2025, 111799

[43] Lingxin Meng^#, Jianyang Fang^#, Xiaoru Lin^#, Rongqiang Zhuang, Lumei Huang, Yesen Li*, Xianzhong Zhang*, Zhide Guo*. Development of radioligands with an albumin-binding moiety of 4-(P-Iodophenyl) butyric acid for theranostic applications. Journal of Controlled Release 382, 113757.

[42] Yesen Li^#, Yanjie Wang^#, Yaoxuan Wang, Jinxiong Huang*, Zhide Guo*. Development and Evaluation of 68Ga-Labeled TMTP1-Based Cyclic Peptide Probes for Targeting Hepatocellular Carcinoma. Molecular Pharmaceutics 2025, 22: 1901-1910.

[41] Huifeng Li^#, Dongsheng Xia^#, Lingxin Meng^#, Jingru Zhang^#, Xuedong Chen, Rongqiang Zhuang, Jinxiong Huang*, Yesen Li*, Jianyang Fang*, Xianzhong Zhang*, Zhide Guo*. FAP-targeted delivery of radioiodinated probes: A progressive albumin-driven strategy for tumor theranostics. Journal of Controlled Release 2025, 382, 113678.

[40] Lingxin Meng^#, Rong Lin^#, Jingru Zhang^#, Huifeng Li, Dongsheng Xia, Zuoquan Zhao, Rongqiang Zhuang, Lumei Huang, Xianzhong Zhang*, Jianyang Fang*, Weibing Miao*, Zhide Guo*. Modification of Asp-Peptide Adapters: Giving the FAP-Targeted Radioligand a "Squirrel Tail". Journal of Medicinal Chemistry 2025, 68: 6576–6587.

[39] Jingchao Li^#, Shengji Lyu^#, Cheng-Ao Li^#, Yi Tang, Fangyang Wang, Qiang Wang, Xin Li, Guo Xu, Hongqing Li, Yueying Zhang, Zhide Guo*, Xiao Chen*, Xianzhong Zhang*. Radionuclide-Activated Luminescence for Cancer Theranostics. Chemistry 2025, 31: e202500296.

[38] Huanhuan Liu, Jia Liu, Yingxi Chen, Hongzhang Yang, Jianyang Fang, Xinying Zeng, Jingru Zhang, Shilan Peng, Yuanyuan Liang, Rongqiang Zhuang*, Gang Liu*, Xianzhong Zhang*, Zhide Guo*. Development of STING probes and visualization of STING in multiple tumor types. European Journal of Nuclear Medicine and Molecular Imaging 2024, 52:401-415

[37] Yuanyuan Liang#, Xueqi Wang#, Yingxi Chen#, Xinying Zeng, Jia Liu, Zuoquan Zhao, Hongzhang Yang, Qinglin Zhang, Jindian Li*, Zhide Guo*, Xianzhong Zhang*. Development and Evaluation of [⁶⁸Ga]Ga-labeled Riboflavin Derivative for RFVT3-Targeted PET Imaging of Melanoma in Mice. Molecular Pharmaceutics 2024, 21:4960-4969

[36] Jia Liu, Yuanyuan Liang, Hongzhang Yang, Xueqi Wang, Xinying Zeng, Rongqiang Zhuang, Jin Du*, Xianzhong Zhang*, Zhide Guo*. Small-molecule radiotracers for visualization of V-domain immunoglobulin suppressor of T cell activation. Journal of Medicinal Chemistry 2024, 67:17690-17700

[35] Jindian Li, Xingfang Hong, Yingxi Chen, Bin Yin, Hongzhang Yang, Changrong Shi, Xinying Zeng, Deliang Zhang*, Zhide Guo*, Xianzhong Zhang*. MicroPET Imaging of Riboflavin Transporter 3 Expression in Myocardial Infarction/Reperfusion Rat Models with Radiofluorinated Riboflavin. ACS Pharmacology & Translational Science 2024, 7:2350-2357

[34] Shilan Peng^#, Yuanyuan Liang^#, Haotian Zhu, Yike Wang, Yun Li, Zuoquan Zhao, Yesen Li, Rongqiang Zhuang, Lumei Huang*, Xianzhong Zhang*, Zhide Guo*. A Nitroreductase Responsive Probe for Early Diagnosis of Pulmonary Fibrosis Disease. Redox Biology 2024, 75:103294

[33] Xueyuan Zeng^#, Hongwu Liu^#, Guolong Huang^#, Yanjie Wang, Wuhao Zhou, Yike Wang, Xuedong Chen, Xingxing Cheng, Rongqiang Zhuang, Jindian Li, Jianyang Fang*, Lumei Huang*, Xianzhong Zhang*, Zhide Guo*. Development of Preladenant-Based Radiotracers for Imaging A2AR in Tumors. Journal of Medicinal Chemistry 2024, 67:13056-13066

[32] Xuedong Chen, Dongsheng Xia, Xueyuan Zeng, Lingxin Meng, Yanjie Wang, Huifeng Li, Jingru Zhang, Zuoquan Zhao, Rongqiang Zhuang, Jianyang Fang*, Xianzhong Zhang*, Zhide Guo*. Rational Design and Pharmacomodulation of ¹⁸F-Labeled Biotin/FAPI-Conjugated Heterodimers. Journal of Medicinal Chemistry 2024, 67:8361-8371

[31] Lingxin Meng#, Jianyang Fang#, Jingru Zhang, Huifeng Li, Dongsheng Xia, Rongqiang Zhuang, Haojun Chen, Jinxiong Huang, Yesen Li*, Xianzhong Zhang*, Zhide Guo*. Rational Design and Comparison of Novel ^99mTc-Labeled FAPI Dimers for Visualization of Multiple Tumor Types. Journal of Medicinal Chemistry. 2024;67:8460-8472

[30] Jianyang Fang^#, Xiaobo Wang^#, Lingxin Meng, Jingru Zhang, Rongqiang Zhuang, Yesen Li, Xianzhong Zhang*, Zhide Guo*. Preclinical Evaluation of ¹³¹I/¹⁸F-Labeled Covalent Small-Molecule Inhibitors for STING Status Imaging. ACS Pharmacology & Translational Science 2024, 7:1783-1794

[29] Jingchao Li^#, Yun Li^#, Jiang Ming^#, Xinying Zeng, Tingting Wang, Hongzhang Yang, Hongwu Liu, Yibo An, Xun Zhang, Rongqiang Zhuang, Xinhui Su*, Zhide Guo*, Xianzhong Zhang*. Progressive Optimization of Lanthanide Nanoparticle Scintillators for Enhanced Triple-Activated Radioluminescence Imaging. Angew Chem Int Ed Engl 2024, e202401683 

[28] Hongzhang Yang^#, Xinying Zeng^#, Jia Liu^#, Jingchao Li, Yun Li, Qinglin Zhang, Linlin Shu, Huanhuan Liu, Xueqi Wang, Yuanyuan Liang, Ji Hu, Lumei Huang*, Zhide Guo*, Xianzhong Zhang*. A Proof-of-Concept Study on Bioorthogonal-based Pretargeting and Signal Amplify Radiotheranostic Strategy. Journal of Nanobiotechnology 2024, 22:101

[27] Jianyang Fang^#, Jingru Zhang, Lingxin Meng, Huifeng Li, Dongsheng Xia, Yaoxuan Wang, Hao Chen, Zhenhuan Liao, Rongqiang Zhuang, Yesen Li, Xianzhong Zhang*, Zhide Guo*. ¹⁸F-Labeled Amidobenzimidazole Analogue for Visualizing STING Expression in Tumor. Molecular pharmaceutics 2024, 21:1942-1951

[26] Yanjie Wang, Yuan Sun, Xueyuan Zeng, Rongqiang Zhuang, Jinxiong Huang, Xianzhong Zhang*, Zhide Guo*, Yesen Li*. Ga–Labeled TMTP1 modified with D-amino acid for Positron Emission Tomography diagnosis of highly metastatic hepatocellular carcinoma. Journal of Medicinal Chemistry 2024, 67:2165-2175

[25] Hongzhang Yang^#, Xinying Zeng^#, Jia Liu^#, Xuejun Wen, Huanhuan Liu, Yuanyuan Liang, Xueqi Wang, Jianyang Fang, Qinglin Zhang, Jindian Li*, Xianzhong Zhang*, Zhide Guo*. Development of Small-molecular-based Radiotracers for PET Imaging of PD-L1 Expression and Guiding the PD-L1 Therapeutics.European Journal of Nuclear Medicine and Molecular Imaging 2024, 51:1582-1592

[24] Xuejun Wen^#, Xueyuan Zeng^#, Jia Liu^#, Xinying Zeng, Yiren Zhang, Xingxing Cheng, Jinxiong Huang, Yesen Li, Rongqiang Zhuang*, Xianzhong Zhang*, Zhide Guo*. In vivo Comparative Study of Radiolabeled Folate Receptor Targeting Albumin Probes for Atherosclerosis Plaque Imaging. Bioconjugate Chemistry 2023, 34:2387-2397.

[23] Huanhuan Liu#, Yuan Sun#, Jindian Li, Yingxi Chen, Jia Liu, Jianyang Fang, Hongzhang Yang, Lixia Feng, Shilan Peng, Rongqiang Zhuang, Zhide Guo*, Xianzhong Zhang*. Development of an 18F-labeled acridone analog for stimulator of interferon genes targeting and visualization in the tumor microenvironment via PET. Molecular Pharmaceutics 2023, 20: 3529-3538

[22] Yizhen Pang^#, Liang Zhao^#, Jianyang Fang^#, Jianhao Chen, Lingxin Meng, Long Sun, Hua Wu, Zhide Guo*, Qin Lin, Haojun Chen*. Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy. Journal of Nuclear Medicine 2023, 64:1449-1455.

[21] Xuejun Wen^#, Pengfei Xu^#, Xinying Zeng^#, Jia Liu, Chao Du, Xueyuan Zeng, Xingxing Cheng, Xueqi Wang, Yuanyuan Liang, Tianzhi Zhao, Hongzhang Yang, Huifeng Li, Lingxin Meng, Jianyang Fang, Hongwu Liu, Zijian Zhou, Jingjing Zhang*, Xianzhong Zhang*, Zhide Guo*, Xiaoyuan Chen*. Development of [¹⁷⁷Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression. European Journal of Nuclear Medicine and Molecular Imaging 2023, 50: 2846-2860.

[20] Zichen Ye^#, Yun Li^#, Jingchao Li, Xinyan Hu, Jinyang Zheng, Gongxin Zhang, Sijin Xiang, Tianbao Zhu, Zhide Guo*, Xiaolan Chen*. Pd@Ir-LOD Multienzyme Utilizing Endogenous Lactate Consumption Cooperates with Photothermal for Tumor Therapy. Nano Research 2023. Doi: 10.1007/s12274-023-5764-1

[19] Xuejun Wen, Changrong Shi, Xinying Zeng, Liang Zhao, Lanlin Yao, Zhida Liu, Lixia Feng, Deliang Zhang, Jinxiong Huang, Yesen Li, Qin Lin, Haojun Chen, Rongqiang Zhuang, Xiaoyuan Chen*, Xianzhong Zhang*, Zhide Guo*. A paradigm of cancer immunotherapy based on 2-[¹⁸F]FDG and anti-PD-L1 mAb combination to enhance the anti-tumor effect. Clinical Cancer Research 2022, 28:2923-2937.

[18] Lingxin Meng^#, Jianyang Fang^#, Liang Zhao^#, Tingting Wang, Pu Yuan, Zuoquan Zhao, Rongqiang Zhuang, Qin Lin, Haojun Chen*, Xiaoyuan Chen*, Xianzhong Zhang*, Zhide Guo*. Rational design and pharmacomodulation of protein-binding theranostic radioligands for targeting fibroblast activation protein. Journal of Medicinal Chemistry 2022, 65:8245-8257.

[17] Xuejun Wen^#, Xinying Zeng^#, Jia Liu, Yiren Zhang, Changrong Shi, Xiaoming Wu, Rongqiang Zhuang, Xiaoyuan Chen*, Xianzhong Zhang*, Zhide Guo*. Synergism of ⁶⁴Cu-labeled RGD with anti-PD-L1 immunotherapy for the long-acting antitumor effect. Bioconjugate Chemistry 2022, 33:2170-2179

[16] Tingting Wang^#, Pengfei Xu^#,*, Jianyang Fang, Cijuan Li, Xinying Zeng, Jia Liu, Lingxin Meng, Rongqiang Zhuang, Xianzhong Zhang*, Xinhui Su*, Zhide Guo*. Synthesis and preclinical evaluation of a ⁶⁸Ga-labeled pyridiny benzamide dimer for malignant melanoma imaging. Molecular Pharmaceutics 2022, 20:1015-1024

[15] Xuejun Wen^#, Xinying Zeng^#, Changrong Shi, Jia Liu, Yiren Zhang, Mengqi Shi, Jingchao Li, Haojun Chen, Rongqiang Zhuang, Xiaoyuan Chen*, Xianzhong Zhang*, Zhide Guo*. Optimum combination of radiopharmaceuticals-based targeting-triggering-therapy effect and PD-L1 blockade immunotherapy. Advanced Therapeutics. Doi: 10.1002/adtp.202200193

[14] Liang Zhao^#, Bo Niu^#, Jianyang Fang^#, Yizhen Pang, Siyang Li, Chengrong Xie, Long Sun, Xianzhong Zhang, Zhide Guo*, Qin Lin, Haojun Chen*. Synthesis, preclinical evaluation, and a pilot clinical PET imaging study of ⁶⁸Ga-labeled FAPI dimer. Journal of Nuclear Medicine 2022, 63:862-868.

[13] Xuejun Wen^#, Pengfei Xu^#, MengqiShi#, Jia Liu, Xinying Zeng, Yiren Zhang, Changrong Shi, Jingchao Li, Zhide Guo*, Xianzhong Zhang*, Pek-Lan Khong*, Xiaoyuan Chen*. Evans blue-modified radiolabeledfibroblast activation protein inhibitor as long-acting cancer therapeutics. Theranostics 2022, 12: 422-433.

[12] Jie Zang^#, Xuejun Wen^#, Rong Lin^#, Xinying Zeng, Chao Wang, Mengqi Shi, Xueyuan Zeng, Jiaying Zhang, Xiaoming Wu, Xianzhong Zhang, Weibing Miao*, Pengfei Xu*, Zhide Guo*, Jingjing Zhang*, Xiaoyuan Chen*. Synthesis, preclinical evaluation and radiation dosimetry of a dual targeting PET tracer [⁶⁸Ga]Ga-FAPI-RGD. Theranostics 2022, 12: 7180-7190.

[11] Xuejun Wen, Changrong Shi, Liu Yang, Xinying Zeng, Xiaoru Lin, Jinxiong Huang, Yesen Li, Rongqiang Zhuang, Haibo Zhu, Zhide Guo*, Xianzhong Zhang*. A radioiodinated FR-β-targeted tracer with improved pharmacokinetics through modification with an albumin binder for imaging of macrophages in AS and NAFL. European Journal of Nuclear Medicine and Molecular Imaging 2022, 49:503-516.

[10] Yiren Zhang, Xuejun Wen, Yanjie Wang, Xia Yang, Yingxi Chen, Xinying Zeng, Yesen Li, Jinxiong Huang, Zhide Guo*, Xianzhong Zhang*. Longitudinal MicroSPECT Imaging of Systemic Sclerosis Model Mice with ^99mTc-HYNFA via FR Targeting. Molecular Pharmaceutics 2023, 20:473-480

[9] Jianyang Fang^#, Lixia Feng^#, Lingxin Meng^#, Xiaobo Wang, Huanhuan Liu, Lumei Huang, Deliang Zhang, Jindian Li, Rongqiang Zhuang, Zhide Guo*, Xianzhong Zhang*. A novel ¹⁸F-labeled agonist for PET imaging of stimulator of interferon gene expression in tumor-bearing mice. European Journal of Nuclear Medicine and Molecular Imaging 2022, 50:27-37.

[8] Lumei Huang^#, Jianyang Fang^#, Shouqiang Hong, Huanhuan Liu, Haotian Zhu, Lixia Feng, Rongqiang Zhuang, Xilin Zhao, Zhide Guo*, Xianzhong Zhang*. MicroPET imaging of bacterial infection with nitroreductase-specific responsive ¹⁸F-labelled nitrogen mustard analogues. European Journal of Nuclear Medicine and Molecular Imaging 2022, 49:2645-2654.

[7] Huanhuan Liu^#, Xiaoru Lin^#, Duo Xu, Jingchao Li, Jianyang Fang, Jindian Li, Lingxin Meng, Xinying Zeng, Yesen Li, Jinxiong Huang, Zhide Guo*, and Xianzhong Zhang*. Radioiodinated ethinylestradiol derivatives for estrogen receptor targeting breast cancer imaging. ACS Medicinal Chemistry Letters 2022, 13:203-210.

[6] Jindian Li^#, Yingxi Chen^#, Chenyu Peng^#, Xingfang Hong^#, Huanhuan Liu, Jianyang Fang, Rongqiang Zhuang, Weimin Pan, Deliang Zhang*, Zhide Guo*, Xianzhong Zhang*. Micro-SPECT Imaging of Acute Ischemic Stroke with Radioiodinated Riboflavin in Rat MCAO Models via Riboflavin Transporter Targeting. ACS Chemical Neuroscience 2022, 13:1966-1973.

[5] Lanlin Yao^#, Xuejun Wen^#, Wei Guo, Jianyang Fang, Xianzhong Zhang, Zhide Guo*, Jinxiong Huang*, Yesen Li¹*. A novel radiolabeled TMTP1 for long-acting hepatocellular carcinoma therapeutics. Molecular Pharmaceutics 2022, 19: 3178-3186.

[4] Lixia Feng, Jianyang Fang, Xinying Zeng, Huanhuan Liu, Jingru Zhang, Zhide Guo*, Rongqiang Zhang*, Xianzhong Zhang*. ⁶⁸Ga-labeled maleimide for blood pool and lymph PET imaging through covalent bonding to serum albumin in vivo. ACS Omega 2022, 7:28597-28604.

[3] Xuejun Wen, Xueyuan Zeng, Xingxing Cheng, Xinying Zeng, Jia Liu, Yiren Zhang, Yesen Li, Haojun Chen, Jinxiong Huang*, Zhide Guo*, Xiaoyuan Chen*, Xianzhong Zhang*. PD-L1-targeted radionuclide therapy combined with αPD-L1 antibody immunotherapy synergistically improves the antitumor effect. Molecular Pharmaceutics 2022, 19:3612-3622.

[2] Duo Xu^#, Xiaoru Lin^#, Xinying Zeng^#, Xuejun Wen, Jingchao Li, Yesen Li, Jinxiong Huang, Xiaoyuan Chen, Zhide Guo*, Xianzhong Zhang*. Radioiodinated 4-(p-iodophenyl) butanoic acid modified estradiol derivative for ER targeting SPECT imaging. Analytical Chemistry 2021, 93:13998-14006.

[1] Jingchao Li^#, Shuqi Dai^#, Ruixue Qin, Changrong Shi, Jiang Ming, Xinying Zeng, Xuejun Wen, Rongqiang Zhuang, Xiaoyuan Chen*, Zhide Guo*, Xianzhong Zhang*. Ligand Engineering of Titanium-Oxo Nanoclusters for Cerenkov Radiation-Reinforced Photo/Chemodynamic Tumor Therapy. ACS Appl Mater Interfaces 2021, 13: 54727-54738.